» Articles » PMID: 15766665

ON01910, a Non-ATP-competitive Small Molecule Inhibitor of Plk1, is a Potent Anticancer Agent

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2005 Mar 16
PMID 15766665
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results in their mitotic arrest and apoptosis. Here we describe the profile of ON01910, a small molecule inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. This compound was not ATP-competitive, but competed for the substrate binding site of the enzyme. In vivo, this compound did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models. ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors.

Citing Articles

Polo-like kinase inhibitors increase AAV production by halting cell cycle progression.

Fisher K, Grafton F, Ispaso F, Tworig J, Derler R, Sonntag F Mol Ther Methods Clin Dev. 2025; 33(1):101412.

PMID: 39968185 PMC: 11834096. DOI: 10.1016/j.omtm.2025.101412.


Three-component synthesis of β-sulfonyl enamines and dienamines enabled by silver(i) acetate.

Koudelka J, Tobrman T RSC Adv. 2025; 15(5):3602-3606.

PMID: 39906634 PMC: 11792975. DOI: 10.1039/d4ra08480b.


Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition.

Coats J, Li S, Tanaka T, Tauro S, Sutherland C, Saurin A Cancer Res Commun. 2024; 4(11):3013-3024.

PMID: 39470360 PMC: 11586712. DOI: 10.1158/2767-9764.CRC-24-0408.


The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.

Biswas B, Huang Y, Craik D, Wang C Chem Sci. 2024; 15(33):13130-13147.

PMID: 39183924 PMC: 11339801. DOI: 10.1039/d4sc01088d.


Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors.

Brauer N, Kempen A, Hernandez D, Sintim H Eur J Med Chem. 2024; 275:116540.

PMID: 38852338 PMC: 11243610. DOI: 10.1016/j.ejmech.2024.116540.